A Study of Ruxolitinib in advanced HER-2 negative breast cancer

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

• IRAS ID

  162078

• Contact name

  Hartmut Kristeleit

• Contact email

  hartmut.kristeleit@gstt.nhs.uk

• Sponsor organisation

  Incyte Corporation

• Eudract number

  2014-002620-26

• Duration of Study in the UK

  1 years, 10 months, 29 days

• Research summary

  To establish if ruxolitinib (also known as INCB018424) is safe and effective when given in combination with a chemotherapy called capecitabine in women who have either advanced or metastatic types of breast cancer and whose Tumour does not over-express a protein called “human epidermal growth factor receptor 2”, or “HER2”. Participants will continue on the study product while progression free.

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  14/NE/1145

• Date of REC Opinion

  16 Oct 2014

• REC opinion

  Further Information Favourable Opinion